A Phase 2 interventional study of FTY720 and Placebo in Multiple Sclerosis, sponsored by Novartis. Completed at 18 sites in Japan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2011-04-21.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 17th largest by enrollment, is the only one that started in 2007, is one of 4 in phase 2, and was the 5th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 30th largest by enrollment of the 64 interventional ones that give a count, is the only one that started in 2007, is one of 12 in phase 2, and was the 5th registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FTY720
Drug: FTY720
FTY720
Drug: FTY720
Drug: Placebo
Administered orally once daily for 6 months
Administered orally once daily for 6 months
Number of Patients Free of Gadolinium-enhanced T1-Weighted Magnetic Resonance Imaging (MRI) Lesions at Both Month 3 and Month 6
Brain Magnetic Resonance Imaging (MRI) was performed at Month 3 and Month 6. Gadolinium-enhancing lesions (active lesions) represent acute inflammatory activity only and dissipate within 2-8 weeks of appearance. MRI scans were analyzed by blinded readers at the central MRI Evaluation Center to ensure consistency. Any Gd-enhanced T1 weighted MRI data obtained less than 14 days after the steroid used to treat MS relapses is invalid and excluded.
Time frame: Month 3 and Month 6
Number of Patients Free of MS Relapse up to Month 6 (Confirmed Relapse Only)
A relapse must have been confirmed by a neurologist and was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS).
Time frame: up to Month 6
Number of Patients Free of New or Newly Enlarged T2 Lesions
The number of T2 lesions were obtained from MRI scans at Screening visit. The numbers of new/newly enlarging T2 lesions were obtained from MRI scans at Month 3 or more. New lesions were identified by comparing each lesion already seen in previous examinations. Lesions expanding throughout several slices were counted as only one lesion.
Time frame: up to Month 3 and up to Month 6
Annualized Relapse Rate (ARR) at 6 Months
Annualized relapse rate (ARR) of the treatment group is calculated by taking the total number of confirmed relapses for all the patients in the treatment group divided by the total number of days on study for all patients in the group and multiplied by 365.25 to obtain the annual rate.
Time frame: 6 Months
| Milestone | FTY720 1.25 mg | FTY720 0.5 mg | Placebo |
|---|---|---|---|
| Started | 57 | 57 | 57 |
| Completed | 48 | 48 | 51 |
| Not completed | 9 | 9 | 6 |
| Withdrew: Adverse event | 6 | 6 | 3 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Discontinued before initiating treatment | 3 | 0 | 0 |
Brain Magnetic Resonance Imaging (MRI) was performed at Month 3 and Month 6. Gadolinium-enhancing lesions (active lesions) represent acute inflammatory activity only and dissipate within 2-8 weeks of appearance. MRI scans were analyzed by blinded readers at the central MRI Evaluation Center to ensure consistency. Any Gd-enhanced T1 weighted MRI data obtained less than 14 days after the steroid used to treat MS relapses is invalid and excluded.
| Participants | FTY720 1.25 mg | FTY720 0.5 mg | Placebo |
|---|---|---|---|
| Number of Patients Free of Gadolinium-enhanced T1-Weighted Magnetic Resonance Imaging (MRI) Lesions at Both Month 3 and Month 6 | 43 | 35 | 21 |
A relapse must have been confirmed by a neurologist and was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS).
| Participants | FTY720 1.25 mg | FTY720 0.5 mg | Placebo |
|---|---|---|---|
| Number of Patients Free of MS Relapse up to Month 6 (Confirmed Relapse Only) | 45 | 45 | 37 |
The number of T2 lesions were obtained from MRI scans at Screening visit. The numbers of new/newly enlarging T2 lesions were obtained from MRI scans at Month 3 or more. New lesions were identified by comparing each lesion already seen in previous examinations. Lesions expanding throughout several slices were counted as only one lesion.
| Participants | FTY720 1.25 mg | FTY720 0.5 mg | Placebo |
|---|---|---|---|
| Month 3 (n = 50, 49, 51) | 30 | 34 | 23 |
| Month 6 (n = 48, 48, 50) | 28 | 31 | 18 |
Annualized relapse rate (ARR) of the treatment group is calculated by taking the total number of confirmed relapses for all the patients in the treatment group divided by the total number of days on study for all patients in the group and multiplied by 365.25 to obtain the annual rate.
| Relapses per year | FTY720 1.25 mg | FTY720 0.5 mg | Placebo |
|---|---|---|---|
| Annualized Relapse Rate (ARR) at 6 Months | 0.407 | 0.512 | 1.131 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FTY720 1.25mg | — | 11/54 (20.4%) | 42/54 (77.8%) |
| FTY720 0.5mg | — | 5/57 (8.8%) | 41/57 (71.9%) |
| Placebo | — | 3/57 (5.3%) | 27/57 (47.4%) |
| Event | FTY720 1.25mg | FTY720 0.5mg | Placebo |
|---|---|---|---|
| BradycardiaCardiac disorders | 8/54 | 3/57 | 0/57 |
| Atrioventricular block second degreeCardiac disorders | 2/54 | 0/57 | 0/57 |
| Sinus bradycardiaCardiac disorders | 1/54 | 0/57 | 0/57 |
| Heart rate decreasedInvestigations | 1/54 | 0/57 | 0/57 |
| Liver function test abnormalInvestigations | 1/54 | 0/57 | 0/57 |
| Facial palsyNervous system disorders | 1/54 | 0/57 | 0/57 |
| Multiple sclerosis relapseNervous system disorders | 1/54 | 0/57 | 0/57 |
| HypotensionVascular disorders | 1/54 | 0/57 | 0/57 |
| Atrioventricular block first degreeCardiac disorders | 0/54 | 1/57 | 0/57 |
| Stress cardiomyopathyCardiac disorders | 0/54 | 0/57 | 1/57 |
| Event | FTY720 1.25mg | FTY720 0.5mg | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 21/54 | 24/57 | 19/57 |
| Liver function test abnormalInvestigations | 18/54 | 12/57 | 3/57 |
| DiarrhoeaGastrointestinal disorders | 6/54 | 3/57 | 3/57 |
| NauseaGastrointestinal disorders | 5/54 | 4/57 | 2/57 |
| HeadacheNervous system disorders | 5/54 | 5/57 | 4/57 |
| ConstipationGastrointestinal disorders | 2/54 | 4/57 | 1/57 |
| PyrexiaGeneral disorders | 2/54 | 2/57 | 4/57 |
| DizzinessNervous system disorders | 3/54 | 4/57 | 1/57 |
| LeukopeniaBlood and lymphatic system disorders | 3/54 | 1/57 | 0/57 |
| LymphopeniaBlood and lymphatic system disorders | 3/54 | 1/57 | 0/57 |
| Age Continuous(years) | FTY720 1.25 mg | FTY720 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 36.0 ± 9.31 | 35.0 ± 9.01 | 35.0 ± 8.93 | 35.3 ± 9.04 |
| Sex: Female, Male(Participants) | FTY720 1.25 mg | FTY720 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 39 | 40 | 39 | 118 |
| Male | 18 | 17 | 18 | 53 |
| Region of Enrollment(participants) | FTY720 1.25 mg | FTY720 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| Japan | 57 | 57 | 57 | 171 |
The record gives a start of Sep 2007 and a primary completion of Feb 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod